Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Jun
13
2022
French Insider Podcast Episode 14: French Investments in the U.S. Wine Industry [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Nov
20
2018
Blog Series Part 7: CMS Proposed Rule on Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Medicaid Fee-For-Service, and Medicaid Managed Care Programs for 2020 and 2021 Sheppard, Mullin, Richter & Hampton LLP
Aug
3
2022
The Government Seeks FCA Liability for Off-Label Use of Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Jun
19
2014
Supreme Court Rules Compliance with Food and Drug Administration (FDA) Labeling Guidelines Does Not Bar Lanham Act False Advertising Suits – POM Wonderful v. Coca-Cola Co. Sheppard, Mullin, Richter & Hampton LLP
Oct
6
2022
BREAKING NEWS: Biden to Pardon Federal Marijuana Possession Convictions Sheppard, Mullin, Richter & Hampton LLP
Dec
27
2014
J.M. Smucker Company Gets Out of a Jam in Food Labelling Case - Caldera v. The J.M. Smucker Co. Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2019
Spate of Recent False Advertising Class Actions Take On Animal Treatment Label Claims Sheppard, Mullin, Richter & Hampton LLP
Jul
14
2023
FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Sheppard, Mullin, Richter & Hampton LLP
Jul
31
2023
UCB, Inc. v. Actavis Laboratories UT, Inc. No. 2021-1924, (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
Sep
1
2023
Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree? Sheppard, Mullin, Richter & Hampton LLP
Oct
11
2023
The U.S. Department of Labor Provides Guidance for Agricultural Employers on the PUMP Act Sheppard, Mullin, Richter & Hampton LLP
Apr
5
2016
Challenge to California Ordinance Prohibiting Mobile Medical Marijuana Dispensaries Goes Up in Smoke Sheppard, Mullin, Richter & Hampton LLP
May
8
2024
OIG Issues Favorable Advisory Opinion Regarding Patient Assistance Funds Sheppard, Mullin, Richter & Hampton LLP
Jan
11
2021
Medi-Cal Rx: California to Transition Medi-Cal Pharmacy Benefits to Fee-For-Service Sheppard, Mullin, Richter & Hampton LLP
Feb
18
2021
Recent FTC Settlement Serves as Reminder For Digital Health Developers Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2009
OTC Drug and Dietary Supplement Labeling: Adverse Event Reporting Information Sheppard, Mullin, Richter & Hampton LLP
Sep
22
2021
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform Sheppard, Mullin, Richter & Hampton LLP
Nov
22
2021
FDA Joins Other Regulators in Focus on AI and Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2018
340B Drug Pricing Program Litigation Update: American Hospital Association, Et Al. v. Azar Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2014
Review – U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines Sheppard, Mullin, Richter & Hampton LLP
Sep
15
2022
California Expands FEHA to Include Off The Job Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
Oct
31
2022
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements Sheppard, Mullin, Richter & Hampton LLP
Dec
6
2022
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program Sheppard, Mullin, Richter & Hampton LLP
Dec
5
2014
Now That That’s Settled: The Status of Class Action Settlements in the Seventh Circuit after Pella, Radioshack and NBTY Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2015
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2023
FDA Clarifies Approach to Pediatric Drug Development Sheppard, Mullin, Richter & Hampton LLP
Aug
28
2015
What’s in a Name? That Which We Call a Biological Product… Sheppard, Mullin, Richter & Hampton LLP
Jan
19
2016
Extending Patentable Life of 3D Printers: Lesson From Pharmaceutical Industry Sheppard, Mullin, Richter & Hampton LLP
Jan
22
2020
New Jersey Court Commands Cannabis Reimbursement in Workers’ Compensation Dispute Sheppard, Mullin, Richter & Hampton LLP
Apr
7
2020
Nota Bene Episode 73: “Quarantine and Chill”: Will COVID-19 Impact the Cannabis Industry? with Whitney Hodges Sheppard, Mullin, Richter & Hampton LLP
Apr
30
2024
FDA Makes Good on Its Promise to Regulate Laboratory-Developed Tests Sheppard, Mullin, Richter & Hampton LLP
Jun
18
2020
President Of Medical Technology Company Charged For Promoting Fake COVID-19 Treatment Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2017
Foreign Investment Under Trump Administration Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins